Top Stories
The complete response letter cited "deficiencies" at a site that manufactures tyrosine kinase inhibitor rivoceranib.
After risvutatug rezetecan met its overall survival endpoint in a Chinese trial, GSK is advancing it outside China across multiple tumour types.
The latest approval marks the first platinum-free regimen cleared for muscle-invasive bladder cancer patients, regardless of cisplatin eligibility.
Sarclisa Escena, administered via the CirCLIQ on-body injector, is approved for multiple myeloma across all indications of the drug's intravenous formulation.
She succeeds Kendra Bence, who left the company last month to pursue a new professional opportunity.
Conference News
Jordi Monés, MD, PhD, to Introduce First Direct-to-Phase 2 Randomized, Controlled Trial of Optogenetic Therapy in Macular DegenerationBenjamin Bakall, MD, PhD, to Present Durable 3-Year REMAIN Follow...
BEIJING, July 10, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), today announced that the Journal of Autoimmunity has published results from a clinical study evaluating orelabrut...
Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026Presentation will highlight recent scientific advances and future opportunities t...
Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical developmentP...
Late-breaking oral presentation highlights early signals of potential visual improvement and patient-reported outcomes of investigational ASP7317 in patients with advanced geographic atrophy (GA)Podiu...
